Major tumor suppressor and oncogenic non-coding RNAs: Clinical relevance in lung cancer

82Citations
Citations of this article
121Readers
Mendeley users who have this article in their library.

Abstract

Lung cancer is the leading cause of cancer deaths worldwide, yet there remains a lack of specific and sensitive tools for early diagnosis and targeted therapies. High-throughput sequencing techniques revealed that non-coding RNAs (ncRNAs), e.g., microRNAs and long ncRNAs (lncRNAs), represent more than 80% of the transcribed human genome. Emerging evidence suggests that microRNAs and lncRNAs regulate target genes and play an important role in biological processes and signaling pathways in malignancies, including lung cancer. In lung cancer, several tumor suppressor/oncogenic microRNAs and lncRNAs function as biomarkers for metastasis and prognosis, and thus may serve as therapeutic tools. In this review, recent work on microRNAs and lncRNAs is introduced and briefly summarized with a focus on potential biological and therapeutic applications.

Cite

CITATION STYLE

APA

Inamura, K. (2017, June 1). Major tumor suppressor and oncogenic non-coding RNAs: Clinical relevance in lung cancer. Cells. MDPI. https://doi.org/10.3390/cells6020012

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free